# Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Source: https://onco.cc/trials/nct05118776/  
OnCo record `nct05118776` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing ASC40 in glioma & glioblastoma, active and no longer recruiting.

## Summary

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM is a phase 3 interventional study registered as NCT05118776, led by Ascletis Pharmaceuticals, and active but no longer recruiting on the registry. Official title: A Phase III Randomised, Double-blind, Placebo-controlled, Multi-centre Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma. Planned enrolment is 136 participants (actual). The study started in 2022-01-21 and primary completion is expected in 2025-06. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05118776
- Phase: 3
- Setting: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma
- Sponsor: Ascletis Pharmaceuticals
- Enrolled: 136

## Sources

- ClinicalTrials.gov NCT05118776: https://clinicaltrials.gov/study/NCT05118776

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [ASC40](https://onco.cc/drugs/asc40/)
- companies: [Ascletis Pharma](https://onco.cc/companies/ascletis/)

---
JSON: https://onco.cc/api/v1/entities/nct05118776.json